Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma

被引：7
|
作者：
Lee, Hyunji [1 ,2 ]
Kim, Minhee [1 ,2 ]
Kim, Seon-Hwan [3 ]
Tran, Quangdon [1 ,2 ]
Kong, Gyeyeong [1 ,2 ]
Kim, Chaeyeong [1 ,2 ]
Kwon, So Hee [4 ]
Park, Jisoo [1 ,2 ,5 ]
Park, Jin Bong [2 ,6 ]
Park, Sungjin [1 ,2 ]
Park, Jongsun [1 ,2 ]
机构：
[1] Chungnam Natl Univ, Dept Pharmacol, Metab Syndrome & Cell Signaling Lab, Inst Canc Res,Coll Med, Daejeon, South Korea
[2] Chungnam Natl Univ, Dept Med Sci, Coll Med, Daejeon, South Korea
[3] Chungnam Natl Univ, Inst Canc Res, Dept Neurosurg, Coll Med, Daejeon, South Korea
[4] Yonsei Univ, Yonsei Inst Pharmaceut Sci, Coll Pharm, Incheon, South Korea
[5] Daejeon Univ, Dept Life Sci, Hyehwa Liberal Arts Coll, LINC Plus Project Grp, Daejeon, South Korea
[6] Chungnam Natl Univ, Dept Physiol, Coll Med, Daejeon, South Korea
来源：
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
基金：
新加坡国家研究基金会;
关键词：
alpha-methylacyl-CoA racemase; glioblastoma; brain; cancer; biomarker;
D O I：
10.3389/fonc.2020.550673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Detection of alpha-methylacyl-CoA racemase (AMACR), a biomarker of prostate cancer, in patient blood samples using a nanoparticle electrochemical biosensor
    Cooney, Matthew M.
    Thompson, Cheryl L.
    Lin, Po-Yuan
    Cheng, Kai-Lun
    McGuffin-Cawley, James D.
    Shieu, Fuh-Sheng
    Samia, Anna C.
    Gupta, Sanjay
    Liu, Chung-Chiun
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (30)
  • [22] Presence of alpha-methylacyl-CoA racemase in liver lesions
    Turkyilmaz, M
    Tretiakova, M
    Davison, J
    Gong, C
    Yang, X
    Hart, J
    MODERN PATHOLOGY, 2003, 16 (01) : 287A - 287A
  • [23] Associations between phytanic acid and alpha-methylacyl-CoA racemase (AMACR) expression in the normal human prostate
    Kataria, Yachana
    Gann, Peter
    Enk, Erika
    Moser, Ann
    Deaton, Ryan
    Lu, Yi
    Nonn, Larisa
    Sharifi, Roohollah
    Deane, Leslie
    Ananthanarayanan, Vijayalakshmi
    Wright-Geise, Margaret
    CANCER RESEARCH, 2012, 72
  • [24] Expression of alpha-methylacyl-CoA racemase (AMACR/P504s) in renal neoplasms.
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 203 - 203
  • [25] Use of alpha-methylacyl-CoA racemase (AMACR) in the diagnosis of prostate cancer (PCA) on needle biopsy.
    Demarzo, A
    Powell, EL
    Isaacs, WB
    Luo, J
    Wanders, RJ
    Gage, WR
    Hicks, J
    Epstein, JI
    JOURNAL OF UROLOGY, 2002, 167 (04): : 330 - 330
  • [26] Alpha-methylacyl-CoA racemase (AMACR) protein is upregulated in early proliferative lesions of the breast irrespective of apocrine differentiation
    Gatalica, Zoran
    Stafford, Phillip
    Vranic, Semir
    HUMAN PATHOLOGY, 2022, 129 : 40 - 46
  • [27] Asymptomatic retinal dysfunction in alpha-methylacyl-CoA racemase deficiency
    Alsalamah, Abrar K.
    Khan, Arif O.
    MOLECULAR VISION, 2021, 27 : 396 - 402
  • [28] Expression of alpha-methylacyl-COA racemase (AMACR) in tissue microarray of 39 cases of diffuse malignant mesothelioma (DMM)
    Davis, D. W.
    Zhai, Q. J.
    Li, W.
    Tan, D.
    Allen, T. C.
    Popper, H. H.
    Cagle, P. T.
    LABORATORY INVESTIGATION, 2008, 88 : 340A - 340A
  • [29] Utility of immunohistochemistry for alpha-methylacyl-coa racemase (AMACR) in distinguishing atrophic prostate cancer from benign atrophy
    Farinola, MA
    Epstein, JI
    MODERN PATHOLOGY, 2003, 16 (01) : 149A - 149A
  • [30] Cytokeratin 5/6 and alpha-methylacyl-coa racemase (AMACR) are useful in evaluating prostate specimens after therapy
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 196 - 197
12345